Biocompatibles’ Drug-Eluting UFE Treatment Would Be Marketed By Terumo
This article was originally published in The Gray Sheet
Executive Summary
Biocompatibles International may await development of a drug-eluting version of its Bead Block microspheres therapy before seeking FDA clearance for uterine fibroid embolization (UFE)
You may also be interested in...
Terumo To End Guidewire And Sheath Distribution Deal With Boston Scientific
Terumo is creating its own U.S. sales force to sell guidewires and sheaths when its existing distribution arrangement with Boston Scientific expires in March 2006
Terumo To End Guidewire And Sheath Distribution Deal With Boston Scientific
Terumo is creating its own U.S. sales force to sell guidewires and sheaths when its existing distribution arrangement with Boston Scientific expires in March 2006
BioSphere Benefits From Broader UFE Awareness, But Remains Short On Profit
Uterine fibroid embolic device maker BioSphere Medical credits Q4 revenue growth to a series of favorable technology assessments, improved marketing management and a high-profile procedure